Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Testicular Germ Cell Tumor
Barbara Ann Karmanos Cancer InstituteSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Testicular Germ Cell Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE City of Hope Medical Center | Phase 2 | BBB |
FILGRASTIM University of Southampton | Phase 2 | BBB |
Carboplatin City of Hope Medical Center | Phase 2 | BBB |
Ifosfamide City of Hope Medical Center | Phase 2 | BBB |
Cyclophosphamide Barbara Ann Karmanos Cancer Institute | Phase 2 | BB |
View all 48 →
Same molecule, other indications
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →